AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$PGNY

Progyny (NASDAQ:PGNY) reports Q3 2026 in line with expectations

Progyny reported Q3 2026 revenue of $341.3M, matching estimates, and adjusted EPS of $0.52, beating estimates by 2.2%. Guidance for Q4 and full-year 2026 was in line with or slightly above expectations. Operating margin improved to 10.3% from 6.9% YoY, while free cash flow margin remained stable at 13.8%.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 10:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 10:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Progyny (NASDAQ:PGNY) reports Q3 2026 in line with expectations — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$PGNYBullishMed
01

Why it matters

The earnings beat reinforces the company's growth narrative, but guidance suggests a steady pace rather than acceleration.

02

Market read

First earnings release for Q3 2026, providing fresh data for traders.

03

What to watch

Potential headwinds from employer cost pressures could dampen future enrollment growth.

Relevance 7/10Novelty 7/10Timing: post-market release

Background

Progyny is a cloud-based benefits platform for employers, focusing on fertility and family planning services.

Company-level read

Ticker impact

$PGNYBullishHigh confidence
Context

Progyny reported Q3 2026 results that slightly beat revenue and EPS estimates and provided guidance in line with expectations.

Expected impact

likely modest upside as market prices in the beat

Evidence & confidence

Both revenue and EPS exceeded consensus, and guidance remains in line, supporting a small bullish bias.

Market effects

Sector

Positive earnings may lift the employee benefits and HR tech sector.

Regional

U.S. market may see a slight uptick in related tech stocks.

Global

Limited to U.S. investors; no global macro impact.

Counterpoint

What could challenge this read

The beat is modest and guidance is only in line; the stock may already be priced for growth, limiting upside.

Key entities

  • Company
    Progyny

    Provider of employee benefits platform.

Read at source← All news

StoryProgyny reports third-quarter revenue growth and raises full-year guidance

Also covered by

3 outlets

Related articles

$PGNYMed

Progyny (PGNY) Q3 2026 Earnings Call Transcript

Progyny (PGNY) reported record revenue and profitability for Q3 2026, with strong cash flow used for growth and share repurchases. The company added 1.3M new covered lives and 85 new clients, raising full-year guidance. Management highlighted strong demand for family building and women's health benefits, diverse client base, and market differentiation. Retention was near 100%, with 20% of clients expanding services. Progyny Select, a new offering, is expected to contribute to long-term growth.

finance.yahoo.com
$PGNYMedAI 8/10

Progyny 3Q 2026: Revenue $341.25M, EPS $0.32 — 10-Q Summary

Progyny reported 3Q 2026 revenue of $341.25M, up 8.9% YoY, and net income of $26.25M, up 89.4% YoY. Growth was driven by increased client and covered-life counts, improving gross margin to 24.5%. Fertility benefits and Progyny Rx revenue rose 11% and 6%, respectively. The company served 607 clients and 7.155M members as of September 30, 2026.

tradingview.com
$PGNYHigh

Progyny Q3 Earnings Call Highlights

Progyny (PGNY) reported Q3 earnings, highlighting a 130 basis point gross margin expansion and $56M in operating cash flow. CEO Anevski noted high client attach rates for Progyny Rx and expects 3M lives to access expanded products by 2027. The company repurchased 3M shares for $83M and plans to taper investments in 2027.

finance.yahoo.com